| scholarly article | Q13442814 |
| P2093 | author name string | Sharon L Reed | |
| Rosa M Andrade | |||
| P2860 | cites work | The genome of the kinetoplastid parasite, Leishmania major | Q22065797 |
| The Genome of the African Trypanosome Trypanosoma brucei | Q22065798 | ||
| The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease | Q22065799 | ||
| The genome of the protist parasite Entamoeba histolytica | Q22122475 | ||
| Thioredoxin reductase | Q24531944 | ||
| Biology of Giardia lamblia | Q24550684 | ||
| Drug targets and mechanisms of resistance in the anaerobic protozoa | Q24550694 | ||
| A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target | Q24623736 | ||
| Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects | Q24652462 | ||
| Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases | Q27003233 | ||
| Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi | Q27657406 | ||
| A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition | Q27671675 | ||
| New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications | Q47861024 | ||
| Differential inhibition of high and low Mr thioredoxin reductases of parasites by organotelluriums supports the concept that low Mr thioredoxin reductases are good drug targets | Q47886605 | ||
| Cryptosporidiosis in Harare, Zimbabwe. | Q50091062 | ||
| Entamoeba histolytica thioredoxin reductase: molecular and functional characterization of its atypical properties. | Q50241498 | ||
| Thioredoxin-linked metabolism in Entamoeba histolytica. | Q54442789 | ||
| Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme. | Q54766074 | ||
| Expression of Trypanosoma congolense trypanothione reductase in Escherichia coli: overproduction, purification, and characterization | Q69529268 | ||
| Auranofin: experience to date | Q70461337 | ||
| Auranofin: a unique oral chrysotherapeutic agent | Q70482149 | ||
| Oxygen uptake in cysts and trophozoites of Giardia lamblia | Q70752528 | ||
| Characterization of the gene encoding serine acetyltransferase, a regulated enzyme of cysteine biosynthesis from the protist parasites Entamoeba histolytica and Entamoeba dispar. Regulation and possible function of the cysteine biosynthetic pathway | Q73133846 | ||
| TREATMENT OF GIARDIA LAMBLIA INFECTION | Q76661002 | ||
| Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study | Q77696967 | ||
| Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis | Q27731122 | ||
| Compartmentation of redox metabolism in malaria parasites | Q27972605 | ||
| Thioredoxin networks in the malarial parasite Plasmodium falciparum | Q27972980 | ||
| Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism | Q28275518 | ||
| Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids | Q28306157 | ||
| Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target | Q28469234 | ||
| Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase | Q28469267 | ||
| Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis | Q28543559 | ||
| Molecular characterization of a 2-Cys peroxiredoxin from the human malaria parasite Plasmodium falciparum | Q30047901 | ||
| Identification of Entamoeba histolytica thiol-specific antioxidant as a GalNAc lectin-associated protein | Q30310731 | ||
| The diversity and evolution of thioredoxin reductase: new perspectives | Q30716821 | ||
| A comparison of the Giardia lamblia trophozoite and cyst transcriptome using microarrays | Q33890040 | ||
| Metabolism and functions of trypanothione in the Kinetoplastida | Q33972467 | ||
| Thioredoxin reductase two modes of catalysis have evolved | Q34049898 | ||
| Thioredoxin reductase as a pathophysiological factor and drug target | Q34049902 | ||
| Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials | Q34058179 | ||
| Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis | Q34460598 | ||
| A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia | Q34583468 | ||
| Comparative genomics of thiol oxidoreductases reveals widespread and essential functions of thiol-based redox control of cellular processes | Q35604029 | ||
| On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases | Q36094494 | ||
| Enteric protozoa in the developed world: a public health perspective. | Q36156094 | ||
| Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. | Q36424454 | ||
| Cryptosporidium species and subtypes and clinical manifestations in children, Peru | Q37028494 | ||
| Treatment of cryptosporidiosis: do we know what we think we know? | Q37778260 | ||
| Recombinant expression and biochemical characterization of an NADPH:flavin oxidoreductase from Entamoeba histolytica | Q38923639 | ||
| Characterization of two E. histolytica proteins that inactivate reactive oxygen species. | Q38923648 | ||
| Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. | Q39169840 | ||
| Entamoeba histolytica: identification of thioredoxin-targeted proteins and analysis of serine acetyltransferase-1 as a prototype example. | Q39436857 | ||
| Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase | Q39580129 | ||
| Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. | Q39599862 | ||
| Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein | Q42019802 | ||
| The amitochondriate eukaryote Trichomonas vaginalis contains a divergent thioredoxin-linked peroxiredoxin antioxidant system. | Q44664089 | ||
| Further trials of metronidazole in amoebic dysentery and amoebic liver abscess | Q45012567 | ||
| An unusual surface peroxiredoxin protects invasive Entamoeba histolytica from oxidant attack. | Q46464785 | ||
| Immunolocalization and enzymatic functional characterization of the thioredoxin system in Entamoeba histolytica. | Q46660068 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 975 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | New drug target in protozoan parasites: the role of thioredoxin reductase | |
| P478 | volume | 6 |
| Q64250608 | Activation Studies of the β-Carbonic Anhydrase from the Pathogenic Protozoan with Amino Acids and Amines |
| Q92697524 | Characterization of Entamoeba histolytica adenosine 5'-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis |
| Q92290892 | Comparative Pathobiology of the Intestinal Protozoan Parasites Giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum |
| Q90585294 | Discrimination Experiments in Entamoeba and Evidence from Other Protists Suggest Pathogenic Amebas Cooperate with Kin to Colonize Hosts and Deter Rivals |
| Q92128951 | Drug repurposing for antimicrobial discovery |
| Q40046014 | Drug susceptibility testing in microaerophilic parasites: Cysteine strongly affects the effectivities of metronidazole and auranofin, a novel and promising antimicrobial |
| Q92946164 | Dynamic Basis for Auranofin Drug Recognition by Thiol-Reductases of Human Pathogens and Intermediate Coordinated Adduct Formation with Catalytic Cysteine Residues |
| Q36869493 | Epidemiology of Domestically Acquired Amebiasis in Japan, 2000-2013. |
| Q53134492 | Metal complexes of 3-(4-bromophenyl)-1-pyridin-2-ylprop-2-en-1-one thiosemicarbazone: cytotoxic activity and investigation on the mode of action of the gold(III) complex. |
| Q93186425 | Parasite-Produced MIF Cytokine: Role in Immune Evasion, Invasion, and Pathogenesis |
| Q28077685 | Recent advances in Entamoeba biology: RNA interference, drug discovery, and gut microbiome |
| Q60907797 | Sulfonamide Inhibition Studies of a New β-Carbonic Anhydrase from the Pathogenic Protozoan |
| Q88984609 | Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of Blastocystis Subtype 1, 4, and 7 Isolates |
Search more.